Pharmacogenetics of Antidepressants: Overview of Dosing Strategies in Major Depressive Disorder
Synopsis
Major depressive disorder is one of the most common psychiatric illnesses worldwide and has low recovery rates. Clinical evidence has suggested that individualized treatment based on pharmacogenetic data in antidepressant users may increase treatment success. Therefore, in this chapter, we focused on the effects of genetic variations in terms of therapeutic response and dose modifications on major depressive disorder patients using selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors.
References
Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69-76. doi:10.1038/gim.2016.80
Shalimova A, Babasieva V, Chubarev VN, et al. Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics. 2021;22(8):485-503. doi:10.2217/pgs-2020-0157
Kabbani D, Akika R, Wahid A, et al. Pharmacogenomics in practice: a review and implementation guide. Front Pharmacol. 2023;14:1189976. doi:10.3389/fphar.2023.1189976
Corponi F, Fabbri C, Serretti A. Pharmacogenetics in Psychiatry. Adv Pharmacol. 2018;83:297-331. doi:10.1016/bs.apha.2018.03.003
Thase ME. Achieving remission and managing relapse in depression. J Clin Psychiatry. 2003;64 Suppl 18:3-7.
Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. doi:10.1176/appi.ajp.163.1.28
Minelli A, Barlati S, Baune BT, European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network. Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review. Eur Neuropsychopharmacol. 2022;59:68-81. doi:10.1016/j.euroneuro.2022.04.007
Ricka N, Pellegrin G, Fompeyrine DA, et al. Predictive biosignature of major depressive disorder derived from physiological measurements of outpatients using machine learning. Sci Rep. 2023;13(1):6332. doi:10.1038/s41598-023-33359-w
Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev. 2001;7(1):25-47. doi:10.1111/j.1527-3458.2001.tb00189.x
van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1993;24(3):203-220. doi:10.2165/00003088-199324030-00003
Fabbri C, Crisafulli C, Calabrò M, et al. Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opin Drug Metab Toxicol. 2016;12(10):1157-1168. doi:10.1080/17425255.2016.1202237
Fu D. Where is it and How Does it Get There - Intracellular Localization and Traffic of P-glycoprotein. Front Oncol. 2013;3:321. doi:10.3389/fonc.2013.00321
de Klerk OL, Nolte IM, Bet PM, et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013;13(4):349-353. doi:10.1038/tpj.2012.16
Canli T, Lesch K-P. Long story short: the serotonin transporter in emotion regulation and social cognition. Nat Neurosci. 2007;10(9):1103-1109. doi:10.1038/nn1964
Stevenson JM. Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy. Pharmacogenomics. 2018;19(3):167-170. doi:10.2217/pgs-2017-0196
van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, et al. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? Front psychiatry. 2020;11:94. doi:10.3389/fpsyt.2020.00094
Nichols CD. Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases. Cardiovasc Psychiatry Neurol. 2009;2009:475108. doi:10.1155/2009/475108
Rudorfer M V, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. 1999;19(3):373-409. doi:10.1023/a:1006949816036
Shulman KI, Herrmann N, Walker SE. Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression. CNS Drugs. 2013;27(10):789-797. doi:10.1007/s40263-013-0097-3
Shalimova A, Babasieva V, Chubarev VN, et al. Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics. 2021;22(8):485-503. doi:10.2217/pgs-2020-0157
Kabbani D, Akika R, Wahid A, et al. Pharmacogenomics in practice: a review and implementation guide. Front Pharmacol. 2023;14:1189976. doi:10.3389/fphar.2023.1189976
Corponi F, Fabbri C, Serretti A. Pharmacogenetics in Psychiatry. Adv Pharmacol. 2018;83:297-331. doi:10.1016/bs.apha.2018.03.003
Thase ME. Achieving remission and managing relapse in depression. J Clin Psychiatry. 2003;64 Suppl 18:3-7.
Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. doi:10.1176/appi.ajp.163.1.28
Minelli A, Barlati S, Baune BT, European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network. Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review. Eur Neuropsychopharmacol. 2022;59:68-81. doi:10.1016/j.euroneuro.2022.04.007
Ricka N, Pellegrin G, Fompeyrine DA, et al. Predictive biosignature of major depressive disorder derived from physiological measurements of outpatients using machine learning. Sci Rep. 2023;13(1):6332. doi:10.1038/s41598-023-33359-w
Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev. 2001;7(1):25-47. doi:10.1111/j.1527-3458.2001.tb00189.x
van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1993;24(3):203-220. doi:10.2165/00003088-199324030-00003
Fabbri C, Crisafulli C, Calabrò M, et al. Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opin Drug Metab Toxicol. 2016;12(10):1157-1168. doi:10.1080/17425255.2016.1202237
Fu D. Where is it and How Does it Get There - Intracellular Localization and Traffic of P-glycoprotein. Front Oncol. 2013;3:321. doi:10.3389/fonc.2013.00321
de Klerk OL, Nolte IM, Bet PM, et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013;13(4):349-353. doi:10.1038/tpj.2012.16
Canli T, Lesch K-P. Long story short: the serotonin transporter in emotion regulation and social cognition. Nat Neurosci. 2007;10(9):1103-1109. doi:10.1038/nn1964
Stevenson JM. Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy. Pharmacogenomics. 2018;19(3):167-170. doi:10.2217/pgs-2017-0196
van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, et al. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? Front psychiatry. 2020;11:94. doi:10.3389/fpsyt.2020.00094
Nichols CD. Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases. Cardiovasc Psychiatry Neurol. 2009;2009:475108. doi:10.1155/2009/475108
Rudorfer M V, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. 1999;19(3):373-409. doi:10.1023/a:1006949816036
Shulman KI, Herrmann N, Walker SE. Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression. CNS Drugs. 2013;27(10):789-797. doi:10.1007/s40263-013-0097-3
Pages
1-12
Published
April 16, 2024
Copyright (c) 2024 Academician Publishing Book Portal
License
LicenseHow to Cite
1.
Said S, Özbey G. Pharmacogenetics of Antidepressants: Overview of Dosing Strategies in Major Depressive Disorder. In: Yamalı C, editor. Current Research in Pharmacy and Pharmaceutical Sciences II-2024 [Internet]. Türkiye: Academician Publishing Book DOI Portal; 2024 [cited 2026 Jul. 13]. pp. 1-12. Available from: https://omp35.books.akademisyen.net/index.php/akya/catalog/book/3054/chapter/13716
